川楝素通过下调c-kit表达抑制GIST-T1细胞增殖并促进其凋亡

胡笑宇; 杨文生; 康政宇; 彭正伟; 李玲; 刘希; 陈诣佳; 张林

doi:10.16016/j.1000-5404.202012232

您当前的位置：

首页 >

文章列表页 >

川楝素通过下调c-kit表达抑制GIST-T1细胞增殖并促进其凋亡

基础医学 | 更新时间：2026-01-09

- 川楝素通过下调c-kit表达抑制GIST-T1细胞增殖并促进其凋亡
- Toosendanin inhibits proliferation and promotes apoptosis of gastrointestinal stromal tumor-T1 cells by down-regulating c-kit expression
- 第三军医大学学报 2021年43卷第13期页码：1235-1242
- 作者机构：
  
  1.610031 成都，西南交通大学医学院
  2.610083 成都，中国人民解放军西部战区总医院全军普外中心胃肠病区
  3.646000 四川泸州，西南医科大学临床医学院
- 作者简介：
  
  [张林, E-mail: flysky8026@aliyun.comZHANG Lin, E-mail: flysky8026@aliyun.com
- 基金信息：
  
  西部战区总医院(原成都军区总医院)创新型人才培养基金资助项目(417325E)
- DOI：10.16016/j.1000-5404.202012232
  中图分类号： R285.5;R73-361;R730.262
- 收稿：2020-12-29，
  
  修回：2021-03-02，
  
  纸质出版：2021-07-15
- 稿件说明：
移动端阅览
胡笑宇, 杨文生, 康政宇, 等. 川楝素通过下调c-kit表达抑制GIST-T1细胞增殖并促进其凋亡[J]. 第三军医大学学报, 2021,43(13):1235-1242.

Xiaoyu HU, Wensheng YANG, Zhengyu KANG, et al. Toosendanin inhibits proliferation and promotes apoptosis of gastrointestinal stromal tumor-T1 cells by down-regulating c-kit expression[J]. Journal of Third Military Medical University, 2021, 43(13): 1235-1242.
胡笑宇, 杨文生, 康政宇, 等. 川楝素通过下调c-kit表达抑制GIST-T1细胞增殖并促进其凋亡[J]. 第三军医大学学报, 2021,43(13):1235-1242. DOI： 10.16016/j.1000-5404.202012232.

Xiaoyu HU, Wensheng YANG, Zhengyu KANG, et al. Toosendanin inhibits proliferation and promotes apoptosis of gastrointestinal stromal tumor-T1 cells by down-regulating c-kit expression[J]. Journal of Third Military Medical University, 2021, 43(13): 1235-1242. DOI： 10.16016/j.1000-5404.202012232.

摘要

目的

研究川楝素(toosendanin，TSN)对胃肠间质瘤细胞增殖及凋亡的影响，并对其相关机制进行初步探索。

方法

不同浓度TSN体外干预GIST-T1细胞，采用CCK-8检测TSN对GIST-T1细胞增殖的影响；根据结果进一步选择实验浓度，分为0、15、30 nmol/L TSN组，50 nmol/L伊马替尼(imatinib，IM)作为阳性对照；流式细胞仪及Hoechst 33342/PI荧光双染检测细胞凋亡及细胞周期；qRT-PCR及Western blot检测c-KIT/PI3K/AKT/mTOR mRNA及相关蛋白表达。

结果

TSN可抑制GIST-T1细胞增殖(

0.01)，其48 h IC

为18.75 nmol/L，72 h IC

为17.93 nmol/L。与对照组相比，15、30 nmol/L TSN组，50 nmol/L IM均可引起不同程度细胞凋亡(

0.01)，但各药物组间凋亡率差异无统计学意义。30 nmol/L TSN可使细胞周期发生S期阻滞(

0.01)。qRT-PCR检测结果显示: 15 nmol/L TSN即可下调GIST-T1细胞c-KIT、PI3K、AKT、mTOR mRNA表达(

0.05，

0.01)。Western blot结果也证实: 15 nmol/L TSN同样抑制了c-KIT、PI3K、AKT、mTOR及其磷酸化蛋白的表达(

0.05，

0.01)。

结论

TSN通过下调c-KIT表达，抑制GIST-T1细胞增殖并促进凋亡，可能是通过PI3K/AKT/mTOR通路发挥作用。

Abstract

Objective

To investigate the effects of toosendanin (TSN) on the proliferation and apoptosis of gastrointestinal stromal tumor (GIST) cells

and to explore the underlying mechanisms.

Methods

GIST-T1 cells were treated with TSN at different concentrations

and then CCK-8 assay was used to detect the effects of TSN on the proliferation of GIST-T1 cells. Subsequently

the experimental concentrations were further divided into 0

30 nmol/L TSN groups

with 50 nmol/L imatinib (IM) as the positive control. Flow cytometry and Hoechst 33342/PI fluorescence double staining were performed to detect cell apoptosis and cell cycle. Finally

the expression of c-KIT

PI3K

AKT and mTOR at mRNA and protein levels were determined by qRT-PCR and Western blotting.

Results

TSN inhibited the proliferation of GIST-T1 cells (

0.01)

and its IC

was 18.75 nmol/L at 48 h and 17.93 nmol/L at 72 h. As compared with the control group

the 15 and 30 nmol/L TSN groups as well as IM group induced cell apoptosis (

0.01)

though the apoptotic rate showed no significance among different drug groups; and 30 nmol/L TSN induced S-phase arrest (

0.01). In addition

qRT-PCR results suggested that 15 nmol/L TSN down-regulated the mRNA expression of c-KIT

PI3K

AKT and mTOR (

0.05

0.01)

and Western blotting confirmed the inhibitory effect of 15 nmol/L TSN on the expression of these proteins and their phosphorylated proteins (

0.05

0.01).

Conclusion

TSN inhibits the proliferation of GIST-T1 cells and promotes apoptosis by down-regulating c-KIT expression

which may function through PI3K/AKT/mTOR pathway.

关键词

Keywords

references

HEMMING M L, LAWLOR M A, ANDERSEN J L, et al . Enhancer domains in gastrointestinal stromal tumor regulate KIT expression and are targetable by BET bromodomain inhibition[J ] . Cancer Res, 2019, 79(5): 994-1009. DOI:10.1158/0008-5472.CAN-18-1888.

DONG Y, LIANG C, ZHANG B, et al . Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells[J ] . Cancer Lett, 2015, 361(1): 137-146. DOI:10.1016/j.canlet.2015.02.044.

NILSSON B, BVMMING P, MEIS-KINDBLOM J M, et al . Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden[J ] . Cancer, 2005, 103(4): 821-829. DOI:10.1002/cncr.20862.

YAN L H, CHEN Z N, LI C J, et al . Prolonging gastrointestinal-stromal-tumor-free life, an optimal suggestion of imatinib intervention ahead of operation[J ] . J Cancer, 2018, 9(21): 3850-3857. DOI:10.7150/jca.25263.

孙祥飞, 高晓东, 沈坤堂. 胃肠间质瘤中伊马替尼继发性耐药机制的研究进展[J]. 中华胃肠外科杂志, 2019, 22(9): 886-890. DOI:10.3760/cma.j.issn.1671-0274.2019.09.014.

SUN X F, GAO X D, SHEN K T. Research advances in the secondary resistance mechanism of imatinib in gastrointestinal stromal tumors[J]. Chin J Gastrointest Surg, 2019, 22(9): 886-890. DOI:10.3760/cma.j.issn.1671-0274.2019.09.014.

KANG Y K, RYU M H, YOO C, et al . Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial[J ] . Lancet Oncol, 2013, 14(12): 1175-1182. DOI: 10.1016/S1470-2045(13)70453-4.

SOHRETOGLU D, HUANG S. Ganoderma lucidum polysaccharides as an anti-cancer agent[J]. Anticancer Agents Med Chem, 2018, 18(5): 667-674. DOI:10.2174/1871520617666171113121246.

KIM B, KIM E Y, LEE E J, et al . Panax notoginseng inhibits tumor growth through activating macrophage to M1 polarization[J ] . Am J Chin Med, 2018, 46(6): 1369-1385. DOI:10.1142/s0192415x18500726.

ZHOU Q, WU X, WEN C, et al . Toosendanin induces caspase-dependent apoptosis through the p38 MAPK pathway in human gastric cancer cells[J ] . Biochem Biophys Res Commun, 2018, 505(1): 261-266. DOI:10.1016/j.bbrc.2018.09.093.

SHI Y L, LI M F. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine[J]. Prog Neurobiol, 2007, 82(1): 1-10. DOI:10.1016/j.pneurobio.2007.02.002.

PEI Z, FU W, WANG G. A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling[J ] . Biochem Biophys Res Commun, 2017, 493(1): 455-460. DOI:10.1016/j.bbrc.2017.08.170.

JU J, QI Z, CAI X, et al . Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells[J ] . Toxicol in Vitro, 2013, 27(1): 232-238. DOI:10.1016/j.tiv.2012.09.013.

史杰, 王芳. 川楝素对TRAIL抗肝癌活性及其机制研究[J]. 浙江中西医结合杂志, 2017, 27(11): 936-939, 946.

SHI J, WANG F. Effect of toosendanin on TRAIL inhibiting hepatocellular carcinoma and the related mechanism[J]. Zhejiang J Integr Tradit Chin West Med, 2017, 27(11): 936-939, 946.

王进, 卢忠心, 何於娟. 川楝素诱导K562细胞自噬性死亡的实验研究[J]. 山东医药, 2013, 53(1): 24-26.

WANG J, LU Z X, HE Y J. Experimental study on autophagy death of K562 cells induced by toosadirachtin[J]. Shandong Med J, 2013, 53(1): 24-26.

CAO L, QU D D, WANG H, et al . Toosendanin exerts an anti-cancer effect in glioblastoma by inducing estrogen receptor β- and p53-mediated apoptosis[J ] . Int J Mol Sci, 2016, 17(11): 1928. DOI: 10.3390/ijms17111928.

GAO T, XIE A, LIU X, et al . Toosendanin induces the apoptosis of human Ewing's sarcoma cells via the mitochondrial apoptotic pathway[J ] . Mol Med Rep, 2019, 20(1): 135-140. DOI:10.3892/mmr.2019.10224..

ZHANG T, LI J, YIN F, et al . Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3[J ] . Oncogene, 2017, 36(47): 6627-6639. DOI:10.1038/onc.2017.270.

WANG G, FENG C C, CHU S J, et al . Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3β/β-catenin pathway[J ] . Int J Oncol, 2015, 47(5): 1767-1774. DOI:10.3892/ijo.2015.3157.

李雨颖, 邵喜英, 金莉婷, 等. 川楝素通过Fas/FasL信号通路诱导人卵巢癌细胞凋亡[J]. 中国中西医结合杂志, 2019, 39(9): 1089-1094. DOI:10.7661/j.cjim.20190729.089.

LI Y Y, SHAO X Y, JIN L T, et al . Apoptosis of qvarian cancer cells induced by toosendanin through Fas/FasL signaling pathway[J ] . Chin J Integr Trad West Med, 2019, 39(9): 1089-1094. DOI:10.7661/j.cjim.20190729.089.

TEWARI D, PATNI P, BISHAYEE A, et al . Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy[J ] . Semin Cancer Biol, 2019. DOI: 10.1016/j.semcancer.2019.12.008.

XIA P, XU X Y. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application[J]. Am J Cancer Res, 2015, 5(5): 1602-1609.

KITAGISHI Y, MATSUDA S. Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute to neuroprotection in a traumatic brain injury[J]. Alzheimers Res Ther, 2013, 5(5): 42. DOI:10.1186/alzrt208.

VIVANCO I, SAWYERS C L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2(7): 489-501. DOI:10.1038/nrc839.

FRANKE T F, YANG S I, CHAN T O, et al . The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase[J ] . Cell, 1995, 81(5): 727-736. DOI:10.1016/0092-8674(95)90534-0.

SARBASSOV D D, GUERTIN D A, ALI S M, et al . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J ] . Science, 2005, 307(5712): 1098-1101. DOI:10.1126/science.1106148.

DUENSING A, MEDEIROS F, MCCONARTY B, et al . Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)[J ] . Oncogene, 2004, 23(22): 3999-4006. DOI:10.1038/sj.onc.1207525.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

环状RNA hsa_circ_0000231与HnRNPK相互作用对乳腺癌增殖、迁移及凋亡的影响

千金藤素增敏多柔比星抑制三阴性乳腺癌细胞增殖活性的机制研究

长链非编码RNA CCAT2在肝癌中的作用及其机制

敲低长链非编码RNA GK-IT1抑制食管鳞状癌细胞增殖和促进凋亡

miR-186-5p负性调控CDCA3对高脂高糖诱导的胰岛β细胞具有保护作用